Lappegård K T, Bjørnstad H, Mollnes T E, Hovland A
Cardiac Care Unit, Division of Internal Medicine, Nordland Hospital, Bodø, Norway.
Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway.
Scand J Immunol. 2015 Sep;82(3):191-8. doi: 10.1111/sji.12328.
Congestive heart failure is associated with increased levels of several inflammatory mediators, and animal studies have shown that infusion of a number of cytokines can induce heart failure. However, several drugs with proven efficacy in heart failure have failed to affect inflammatory mediators, and anti-inflammatory therapy in heart failure patients has thus far been disappointing. Hence, to what extent heart failure is caused by or responsible for the increased inflammatory burden in the patient is still unclear. Over the past couple of decades, resynchronization therapy with a biventricular pacemaker has emerged as an effective treatment in a subset of heart failure patients, reducing both morbidity and mortality. Such treatment has also been shown to affect the inflammation associated with heart failure. In this study, we review recent data on the association between heart failure and inflammation, and in particular how resynchronization therapy can affect the inflammatory process.
充血性心力衰竭与多种炎症介质水平升高有关，动物研究表明，输注多种细胞因子可诱发心力衰竭。然而，几种已证实对心力衰竭有效的药物未能影响炎症介质，迄今为止，心力衰竭患者的抗炎治疗效果令人失望。因此，心力衰竭在多大程度上是由患者炎症负担增加所致或导致炎症负担增加仍不清楚。在过去几十年中，双心室起搏器再同步治疗已成为一部分心力衰竭患者的有效治疗方法，可降低发病率和死亡率。这种治疗也已被证明会影响与心力衰竭相关的炎症。在本研究中，我们回顾了关于心力衰竭与炎症之间关联的最新数据，特别是再同步治疗如何影响炎症过程。
